Suchergebnisse - Jonathan D. Cheng

Treffer weiter einschränken
  1. 1
    FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells

    FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells von Hyung‐Ok Lee, Stefanie Mullins, Janusz Franco‐Barraza, Matthildi Valianou, Edna Cukierman, Jonathan D. Cheng

    Veröffentlicht 2011
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  2. 2
    Activatable Near-Infrared Fluorescent Probe for <i>In Vivo</i> Imaging of Fibroblast Activation Protein-alpha

    Activatable Near-Infrared Fluorescent Probe for <i>In Vivo</i> Imaging of Fibroblast Activation Protein-alpha von Jinbo Li, Kai Chen, Hongguang Liu, Kai Cheng, Meng Yang, Jiping Zhang, Jonathan D. Cheng, Yan Zhang, Zhen Cheng

    Veröffentlicht 2012
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  3. 3
    Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma Is Associated With Significantly Improved Survival

    Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma Is Associated With Significantly Improved Survival von Adam C. Berger, Jeffrey M. Farma, Walter J. Scott, Gary M. Freedman, Louis M. Weiner, Jonathan D. Cheng, Hao Wang, Melvyn Goldberg

    Veröffentlicht 2005
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  4. 4
    Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from <scp>KEYNOTE</scp>‐012

    Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from <scp>KEYNOTE</scp>‐012 von Makoto Tahara, Kei Muro, Yasuhisa Hasegawa, Hyun Cheol Chung, Chia‐Chi Lin, Bhumsuk Keam, Kenichi Takahashi, Jonathan D. Cheng, Yung‐Jue Bang

    Veröffentlicht 2017
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  5. 5
    Photodynamic Molecular Beacon Triggered by Fibroblast Activation Protein on Cancer-Associated Fibroblasts for Diagnosis and Treatment of Epithelial Cancers

    Photodynamic Molecular Beacon Triggered by Fibroblast Activation Protein on Cancer-Associated Fibroblasts for Diagnosis and Treatment of Epithelial Cancers von Pui‐Chi Lo, Juan Chen, Klara Stefflova, Michael S. Warren, Roya Navab, Bizhan Bandarchi, Stefanie Mullins, Ming‐Sound Tsao, Jonathan D. Cheng, Gang Zheng

    Veröffentlicht 2008
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  6. 6
    Long-Term Results of Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: A Phase II Trial of the Radiation Therapy Oncology Group (RTOG 99-14)

    Long-Term Results of Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: A Phase II Trial of the Radiation Therapy Oncology Group (RTOG 99-... von Adam S. Garden, Jonathan Harris, Andy Trotti, Christopher U. Jones, Luis A. Carrascosa, Jonathan D. Cheng, Sharon Spencer, Arlene A. Forastiere, Randal S. Weber, K. Kian Ang

    Veröffentlicht 2008
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  7. 7
    Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: Radiation Therapy Oncology Group Phase II Trial 99-14

    Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: Radiation Therapy Oncology Group Phase II Trial 99-14 von K. Kian Ang, Jonathan Harris, Adam S. Garden, Andy Trotti, Christopher U. Jones, Luis A. Carrascosa, Jonathan D. Cheng, Sharon Spencer, Arlene A. Forastiere, Randal S. Weber

    Veröffentlicht 2005
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  8. 8
    Dipeptidyl peptidase 8/9-like activity in human leukocytes

    Dipeptidyl peptidase 8/9-like activity in human leukocytes von Marie-Berthe Maes, Véronique Dubois, Inger Brandt, Anne‐Marie Lambeir, Pieter Van der Veken, Koen Augustyns, Jonathan D. Cheng, Xin Chen, Simon Scharpé, Ingrid De Meester

    Veröffentlicht 2007
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  9. 9
    Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold

    Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold von Koen Jansen, Leen Heirbaut, Jonathan D. Cheng, Jurgen Joossens, O.V. Ryabtsova, Paul Cos, Louis Maes, Anne‐Marie Lambeir, Ingrid De Meester, Koen Augustyns, Pieter Van der Veken

    Veröffentlicht 2013
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  10. 10
    Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

    Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study von Rita Nanda, Laura Q.M. Chow, Elizabeth Claire Dees, Raanan Berger, Shilpa Gupta, Ravit Geva, Lajos Pusztai, Kumudu Pathiraja, Gursel Aktan, Jonathan D. Cheng, Vassiliki Karantza, Laurence Buisseret

    Veröffentlicht 2016
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  11. 11
    Individualized Patient Dosing in Phase I Clinical Trials: The Role of Escalation With Overdose Control in PNU-214936

    Individualized Patient Dosing in Phase I Clinical Trials: The Role of Escalation With Overdose Control in PNU-214936 von Jonathan D. Cheng, James S. Babb, Corey J. Langer, Steinar Aamdal, Francisco Robert, Lars Engelhardt, Olov Fernberg, Joan H. Schiller, G. Forsberg, R. Katherine Alpaugh, Louis M. Weiner, André Rogatko

    Veröffentlicht 2004
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  12. 12
    Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study

    Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study von Kevin J. Harrington, Anthony Kong, Nicolas Mach, Jason Chesney, Beatriz Castelo Fernández, Danny Rischin, Ezra E.W. Cohen, Hoi-Shen Radcliffe, Burak Gümüşçü, Jonathan D. Cheng, Wendy Snyder, Lillian L. Siu

    Veröffentlicht 2020
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  13. 13
    Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer

    Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer von Kalyani Narra, Stefanie Mullins, Hyung-Ok Lee, Brenda Strzemkowski-Brun, K. Magalong, Victoria J. Christiansen, Patrick A. McKee, Brian L. Egleston, Steven J. Cohen, Louis M. Weiner, Neal J. Meropol, Jonathan D. Cheng

    Veröffentlicht 2007
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  14. 14
    Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer

    Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esop... von André Konski, Tianyu Li, Michael Christensen, Jonathan D. Cheng, Jian Q. Yu, Kevin Crawford, Oleh Haluszka, Jeffrey L. Tokar, Walter J. Scott, Neal J. Meropol, Steven J. Cohen, Alan H. Maurer, Gary M. Freedman

    Veröffentlicht 2012
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  15. 15
    PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

    PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer von Jennifer H. Yearley, Christopher J. Gibson, Ni Yu, Christina Moon, Erin Murphy, Jonathan Juco, Jared Lunceford, Jonathan D. Cheng, Laura Q.M. Chow, Tanguy Y. Seiwert, Masahisa Handa, Joanne E. Tomassini, Terrill K. McClanahan

    Veröffentlicht 2017
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  16. 16
    Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

    Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer von Janice M. Mehnert, Andréa Varga, Marcia S. Brose, Rahul Aggarwal, Chia‐Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A. Piha‐Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam

    Veröffentlicht 2019
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  17. 17
    IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

    IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade von Mark Ayers, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, David R. Kaufman, Andrew Albright, Jonathan D. Cheng, Shijun Kang, Veena Shankaran, Sarina A. Piha‐Paul, Jennifer H. Yearley, Tanguy Y. Seiwert, Antoni Ribas, Terrill K. McClanahan

    Veröffentlicht 2017
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  18. 18
    A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patients

    A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patients von Robert A. Schnoll, Randi L. Rothman, Dustin B. Wielt, Caryn Lerman, Holly Pedri, Hao Wang, James S. Babb, Suzanne M. Miller, Benjamin Movasas, Eric J. Sherman, John A. Ridge, M. Unger, Corey J. Langer, Melvyn Goldberg, Walter J. Scott, Jonathan D. Cheng

    Veröffentlicht 2005
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  19. 19
    Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

    Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study von Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister, Francis P. Worden, Stephen V. Liu, Jill Gilbert, Nabil F. Saba, Jared Weiss, Lori J. Wirth, Ammar Sukari, Hyunseok Kang, Michael K. Gibson, Erminia Massarelli, Steven Powell, Amy Meister, Xinxin Shu, Jonathan D. Cheng, Robert I. Haddad

    Veröffentlicht 2017
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  20. 20
    Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

    Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer von Janice M. Mehnert, Anshuman Panda, Judy Zhong, Kim M. Hirshfield, Sherri Damare, Katherine Lane, Levi Sokol, Mark N. Stein, Lorna Rodriguez-Rodriquez, Howard L. Kaufman, Siraj M. Ali, Jeffrey S. Ross, Dean C. Pavlick, Gyan Bhanot, Eileen White, Robert S. DiPaola, Ann Lovell, Jonathan D. Cheng, Shridar Ganesan

    Veröffentlicht 2016
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: